Is GKOS or PLSE more profitable?

Pulse Biosciences has a net margin of 0.00% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Pulse Biosciences N/A -86.67% -73.61%

Do analysts rate PLSE or STVN?

Pulse Biosciences presently has a consensus price target of $30.67, indicating a potential upside of 21.07%. Given Pulse Biosciences' higher possible upside, research analysts clearly believe Pulse Biosciences is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulse Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger earnings and valuation, LQDA or PLSE?

Liquidia has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 34.74 -$68.92M $0.14 441.79 Pulse Biosciences $350K 5,008.83 -$72.78M -$1.10 N/A

Pulse Biosciences (PLSE) Competitors

$25.33 -1.61 (-5.98%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$25.36 +0.04 (+0.14%)

As of 06/5/2026 07:18 PM Eastern

Compare

PLSE vs. GKOS, STVN, BLCO, LQDA, and LIVN

Should you buy Pulse Biosciences stock or one of its competitors? MarketBeat compares Pulse Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulse Biosciences include Glaukos (GKOS), Stevanato Group (STVN), Bausch + Lomb (BLCO), Liquidia (LQDA), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does Pulse Biosciences compare to Glaukos?

Glaukos (NYSE:GKOS) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Pulse Biosciences has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	14.44	-$187.69M	-$3.28	N/A
Pulse Biosciences	$350K	5,008.83	-$72.78M	-$1.10	N/A

Pulse Biosciences has a net margin of 0.00% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Pulse Biosciences	N/A	-86.67%	-73.61%

In the previous week, Glaukos had 1 more articles in the media than Pulse Biosciences. MarketBeat recorded 2 mentions for Glaukos and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.00 beat Glaukos' score of 0.37 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Glaukos	Neutral
Pulse Biosciences	Positive

Glaukos has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

99.0% of Glaukos shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Glaukos presently has a consensus target price of $146.17, indicating a potential upside of 17.13%. Pulse Biosciences has a consensus target price of $30.67, indicating a potential upside of 21.07%. Given Pulse Biosciences' higher possible upside, analysts clearly believe Pulse Biosciences is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Pulse Biosciences beats Glaukos on 9 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Stevanato Group?

Pulse Biosciences (NASDAQ:PLSE) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Stevanato Group has a net margin of 11.76% compared to Pulse Biosciences' net margin of 0.00%. Stevanato Group's return on equity of 10.27% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Stevanato Group	11.76%	10.27%	6.08%

Pulse Biosciences presently has a consensus price target of $30.67, indicating a potential upside of 21.07%. Given Pulse Biosciences' higher possible upside, research analysts clearly believe Pulse Biosciences is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

77.0% of Pulse Biosciences shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Stevanato Group has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	5,008.83	-$72.78M	-$1.10	N/A
Stevanato Group	€1.34B	4.19	€158.21M	€0.59	31.49

In the previous week, Stevanato Group had 4 more articles in the media than Pulse Biosciences. MarketBeat recorded 5 mentions for Stevanato Group and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.00 beat Stevanato Group's score of 0.67 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Pulse Biosciences	Positive
Stevanato Group	Positive

Pulse Biosciences has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Summary

Stevanato Group beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Pulse Biosciences has a net margin of 0.00% compared to Bausch + Lomb's net margin of -4.21%. Bausch + Lomb's return on equity of 3.60% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Pulse Biosciences	N/A	-86.67%	-73.61%

In the previous week, Bausch + Lomb had 4 more articles in the media than Pulse Biosciences. MarketBeat recorded 5 mentions for Bausch + Lomb and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.00 beat Bausch + Lomb's score of 0.72 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Bausch + Lomb	Positive
Pulse Biosciences	Positive

Bausch + Lomb currently has a consensus price target of $17.92, indicating a potential upside of 15.73%. Pulse Biosciences has a consensus price target of $30.67, indicating a potential upside of 21.07%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Bausch + Lomb has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

Pulse Biosciences has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.08	-$360M	-$0.62	N/A
Pulse Biosciences	$350K	5,008.83	-$72.78M	-$1.10	N/A

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Pulse Biosciences beats Bausch + Lomb on 10 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Liquidia presently has a consensus price target of $55.63, indicating a potential downside of 10.06%. Pulse Biosciences has a consensus price target of $30.67, indicating a potential upside of 21.07%. Given Pulse Biosciences' higher possible upside, analysts clearly believe Pulse Biosciences is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Liquidia has a net margin of 7.74% compared to Pulse Biosciences' net margin of 0.00%. Liquidia's return on equity of 46.82% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Pulse Biosciences	N/A	-86.67%	-73.61%

In the previous week, Liquidia had 5 more articles in the media than Pulse Biosciences. MarketBeat recorded 6 mentions for Liquidia and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.00 beat Liquidia's score of -0.15 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Liquidia	Neutral
Pulse Biosciences	Positive

64.5% of Liquidia shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Liquidia has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	34.74	-$68.92M	$0.14	441.79
Pulse Biosciences	$350K	5,008.83	-$72.78M	-$1.10	N/A

Liquidia has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Summary

Liquidia beats Pulse Biosciences on 11 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

LivaNova has a net margin of 7.48% compared to Pulse Biosciences' net margin of 0.00%. LivaNova's return on equity of 16.48% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Pulse Biosciences	N/A	-86.67%	-73.61%

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, LivaNova had 2 more articles in the media than Pulse Biosciences. MarketBeat recorded 3 mentions for LivaNova and 1 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 1.00 beat LivaNova's score of 0.09 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
LivaNova	Neutral
Pulse Biosciences	Positive

LivaNova has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

LivaNova currently has a consensus target price of $79.38, indicating a potential upside of 9.69%. Pulse Biosciences has a consensus target price of $30.67, indicating a potential upside of 21.07%. Given Pulse Biosciences' higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Pulse Biosciences has lower revenue, but higher earnings than LivaNova. Pulse Biosciences is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.11
Pulse Biosciences	$350K	5,008.83	-$72.78M	-$1.10	N/A

Summary

LivaNova beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

Get Pulse Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLSE vs. The Competition

Export

Metric	Pulse Biosciences	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.75B	$7.25B	$6.68B	$11.99B
Dividend Yield	N/A	1.20%	2.67%	5.55%
P/E Ratio	-23.03	45.87	24.06	23.63
Price / Sales	5,008.83	73.75	519.33	112.45
Price / Cash	N/A	24.67	42.23	54.60
Price / Book	21.29	6.95	9.73	6.35
Net Income	-$72.78M	$159.22M	$3.57B	$337.59M
7 Day Performance	1.32%	-2.59%	-1.28%	-2.52%
1 Month Performance	29.30%	1.84%	1.38%	-0.03%
1 Year Performance	48.13%	-1.02%	23.93%	25.34%

Pulse Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLSE Pulse Biosciences	3.0089 of 5 stars	$25.33 -6.0%	$30.67 +21.1%	+48.1%	$1.75B	$350K	N/A	140	Positive News Analyst Forecast Gap Down
GKOS Glaukos	2.4388 of 5 stars	$111.13 +7.8%	$146.17 +31.5%	+34.1%	$6.06B	$507.44M	N/A	1,094
STVN Stevanato Group	2.3485 of 5 stars	€18.92 +0.3%	N/A	-21.9%	€5.73B	€1.34B	32.07	6,010	Analyst Forecast
BLCO Bausch + Lomb	4.1321 of 5 stars	$14.97 -2.7%	$17.92 +19.7%	+32.4%	$5.49B	$5.10B	N/A	13,000	Analyst Forecast
LQDA Liquidia	2.2763 of 5 stars	$55.11 -6.2%	$50.88 -7.7%	+241.0%	$5.22B	$158.32M	393.67	50	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLSE) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulse Biosciences (PLSE) Competitors

PLSE vs. GKOS, STVN, BLCO, LQDA, and LIVN

How does Pulse Biosciences compare to Glaukos?

Summary

How does Pulse Biosciences compare to Stevanato Group?

Summary

How does Pulse Biosciences compare to Bausch + Lomb?

Summary

How does Pulse Biosciences compare to Liquidia?

Summary

How does Pulse Biosciences compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulse Biosciences (PLSE) Competitors

PLSE vs. GKOS, STVN, BLCO, LQDA, and LIVN

How does Pulse Biosciences compare to Glaukos?

Which has better valuation and earnings, GKOS or PLSE?

Is GKOS or PLSE more profitable?

Does the media favor GKOS or PLSE?

Which has more risk and volatility, GKOS or PLSE?

Do institutionals and insiders believe in GKOS or PLSE?

Do analysts recommend GKOS or PLSE?

Summary

How does Pulse Biosciences compare to Stevanato Group?

Is PLSE or STVN more profitable?

Do analysts rate PLSE or STVN?

Do institutionals & insiders have more ownership in PLSE or STVN?

Which has higher valuation & earnings, PLSE or STVN?

Does the media prefer PLSE or STVN?

Which has more volatility and risk, PLSE or STVN?

Summary

How does Pulse Biosciences compare to Bausch + Lomb?

Is BLCO or PLSE more profitable?

Does the media prefer BLCO or PLSE?

Do analysts rate BLCO or PLSE?

Which has more risk & volatility, BLCO or PLSE?

Which has preferable earnings and valuation, BLCO or PLSE?

Do institutionals and insiders have more ownership in BLCO or PLSE?

Summary

How does Pulse Biosciences compare to Liquidia?

Do analysts prefer LQDA or PLSE?

Is LQDA or PLSE more profitable?

Does the media prefer LQDA or PLSE?

Do insiders & institutionals have more ownership in LQDA or PLSE?

Which has stronger earnings and valuation, LQDA or PLSE?

Which has more volatility & risk, LQDA or PLSE?

Summary

How does Pulse Biosciences compare to LivaNova?

Is LIVN or PLSE more profitable?

Do insiders and institutionals have more ownership in LIVN or PLSE?

Does the media prefer LIVN or PLSE?

Which has more risk and volatility, LIVN or PLSE?

Do analysts prefer LIVN or PLSE?

Which has better valuation and earnings, LIVN or PLSE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools